Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 40Lymphoma 7Waldenstrom Macroglobulinemia 3Recurrence 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Plasmacytoma 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × ixazomib × Clear all
NCT03547700 2026-05-06

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
11 enrolled 10 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡